Overall Results by Subgroup and Dose5

Results
Subgroup

Overall-Pooled
VYNDAQEL vs Placebo

TTR Genotype
ATTRm (24%)
ATTRwt (76%)

NYHA Baseline
Class I or II (68%)
Class III (32%)

Dose
80 mg (40%) vs Placebo (40%)
20 mg (20%) vs Placebo (40%)

F-S Method*
(Win Ratio 95% CI)
4
2
1
0.5
Favors tafamidis
Favors Placebo
All-cause Mortality
Hazard Ratio (95% CI)
0.25
0.5
1
2
Favors tafamidis
Favors Placebo
Cardiovascular Hospitalization Frequency Risk Ratio (95% CI)
0.25
0.5
1
2
Favors tafamidis
Favors Placebo

ATTRm: mutant ATTR-CM; ATTRwt: wild-type ATTR-CM; CI: confidence interval; F-S: Finkelstein–Schoenfeld; NYHA: New York Heart Association; TTR: transthyretin.